HNN3.0
Register
Register
Register

Inovarion

Company (SME)

www.inovarion.comParis, France
6 profile visits

About

Inovarion is a life sciences research and development centre based in Paris, founded in 2013. We design and carry out research with our partners, from targeted studies to multi-year programmes.
Our work covers immunomonitoring and immune profiling of patient samples, preclinical and in vivo models, digital pathology, translational research on patient samples and cohorts, target validation, drug discovery, bioinformatics and data management.
Since 2013 we have worked with more than 80 laboratories on over 550 research projects, for public research institutions such as Inserm, CNRS, Institut Curie, Collège de France and CEA, as well as for companies. We have co-authored more than 190 peer-reviewed publications, including in Nature Communications, Blood and European Urology.
Within a Horizon Europe consortium, we can take on both experimental and analytical tasks, for instance preclinical models, biomarker validation in patient cohorts, the integration and harmonisation of clinical and biological data across centres, or the data management plan and FAIR requirements.

Social media

Representatives

Collaborative Projects Lead

Inovarion

Marketplace (1)

  • Project cooperation

    Life sciences R&D centre offers bioinformatics, biomarker validation and data management to Cluster 1 Health consortia

    We are a Paris-based R&D centre looking to join a consortium for the 2027 Cluster 1 Health calls, as a research partner. We can take on bioinformatics, multi-omic analysis, biomarker validation in cohorts, data harmonisation and FAIR data management.

    • Partner seeks Consortium/Coordinator
    • Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
    • Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
    • Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
    • Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
    • Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
    • Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
    • Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
    • Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
    Author

    Collaborative Projects Lead at Inovarion

    Paris, France